Michael J. Birrer, MD of Massachusetts General Hospital discusses multiplex testing and next generation sequencing in metastatic ovarian cancer at SGO 2016.
Transcription:
So this is a really high question. Because there are many many commercially available platforms which provide a lot of genomic data both for the physician and the patient. I and I think frankly is more often than not confusing. For both individuals. What I recommend because. Ovarian cancer is a disease of genomics chaos. There’s a very low frequency of actionable mutations and even when you see a mutation in a gene that you think is actionable. Are we don’t have the and understand the biology to tell you where that’s going to mean anything for the patient. So I limit my sequencing to those genes that would define homologous recombination defense. So these would be BRCA 1 and BRCA 2 and many the genes are low. In the Fanconi DNA repair pathway those are important because first of all if they’re associating a germ line it has implications. For the family. And risk of development of a very cancer and to now that part of the class of agents called part inhibitors have been approved it is fair to assume their view of a patient who has a mutation one of those genes that their tumor may be responsive department Evers.